After-Hours Movers: KBH, WOR, IONQ, TLSI, INNV

KB Home (KBH) rose 2% post-market on strong sector signals. Worthington Enterprises (WOR) surged 14% after Q1 earnings beat estimates. IonQ (IONQ) climbed 8% on quantum error correction milestone. TriSalus Life Sciences (TLSI) jumped 28% after FDA clearance. InnovAge (INNV) dropped 12% on secondary stock offering.

Original reporting
Published Sep 22, 2026, 8:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 22, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$KBH
Bullish
medium confidence
Mentioned
$KBH · $WOR · $IONQ · $TLSI · $INNV
Relevance
5/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$KBHBullishMed
01

Why it matters

Each ticker experienced a material price move tied to fresh corporate news, offering short‑term trading opportunities.

02

Market read

The article provides fresh, actionable news for each company, with mixed sentiment across sectors.

03

What to watch

Potential supply‑chain constraints for Worthington and regulatory timelines for IonQ's technology could affect longer‑term outcomes.

Relevance 5/10Novelty 6/10Timing: after‑hours today

Background

After‑hours market recap highlighting five U.S. listed companies with distinct catalysts.

Company-level read

Ticker impact

$KBHBullishMedium confidence
Context

KB Home rose 2% in post‑market trading after sector read‑throughs and stronger buyer demand.

Expected impact

Potential short‑term upside if demand holds.

Evidence & confidence

2% after‑hours gain suggests momentum; no new earnings data, but demand cues may attract traders.

$WORBullishHigh confidence
Context

Worthington Enterprises surged 14% after reporting Q1 EPS of $0.82 beating estimates and 13.2% YoY sales growth.

Expected impact

Likely continued buying pressure in early session.

Evidence & confidence

Quarterly beat and revenue growth are fresh material; 14% move indicates significant market reaction.

$IONQBullishMedium confidence
Context

IonQ climbed 8% after announcing a real‑time quantum error‑correction decoder that runs on a standard CPU.

Expected impact

Short‑term rally may persist as investors price the breakthrough.

Evidence & confidence

First‑time claim of end‑to‑end error correction is novel and could boost valuation.

$TLSIBullishHigh confidence
Context

TriSalus Life Sciences jumped 28% after receiving FDA 510(k) clearance for its TriNav® Advance device.

Expected impact

Expect further upside as sales ramp up.

Evidence & confidence

FDA clearance is a material catalyst; 28% move reflects strong market response.

$INNVBearishMedium confidence
Context

InnovAge fell 12% following the launch of a 10 million‑share secondary offering with an over‑hang.

Expected impact

Downward pressure likely to continue until offering completes.

Evidence & confidence

Large secondary raise creates supply shock; 12% drop signals negative sentiment.

Market effects

Housing demand, building products, quantum tech, med‑tech, and healthcare financing each see fresh catalysts.

U.S. equities see varied moves; sector breadth may influence broader indices.

Limited to U.S. listed companies; no direct global macro effect.

Counterpoint

The sharp moves may be over‑reactions; fundamentals could temper gains for KBH, WOR, IONQ, TLSI, while INNV's dilution risk may be overstated.

Key entities

  • KB Home

    Homebuilder

  • Worthington Enterprises

    Building products manufacturer

  • IonQ

    Quantum computing firm

  • TriSalus Life Sciences

    Medical device maker

  • InnovAge Holding Corp.

    Healthcare platform

Related articles

$TLSIHigh

TriSalus Life Sciences Reports 11.3% Q3 Revenue Growth to $12.9 Million, Revises 2026 Guidance

TriSalus Life Sciences (TLSI) reported Q3 2026 revenue of $12.9M, up 11.3% YoY, and revised 2026 guidance to $46M-$48M. Gross margin improved to 86.2%, and operating losses narrowed. The company received FDA clearance for TriNav Advance and expects higher Medicare reimbursement rates. CEO Mary Szela cited commercial growth but noted slower sales rep productivity. Cash reserves stood at $41.1M post-equity offering.

$IONQMed

IonQ Named Market Shaper in Gartner’s 2026 Emerging Market Quadrant for Quantum Computing

IonQ (IONQ) was named a Market Shaper in Gartner's 2026 Quantum Computing quadrant, recognizing its advanced systems and commercial support. The company cited its full-stack platform and fault-tolerant progress. IonQ also advanced in DARPA's Quantum Benchmarking Initiative and received $7.5M for a quantum networking project. It plans to deploy Superion 256 systems to research institutions.

$QBTSMed

D-Wave Quantum Falls 7% on Wider-Than-Expected Loss Despite Revenue Beat; Rigetti Slides 3%, IonQ Holds Steady

D-Wave Quantum (QBTS) shares fell 7% after Q3 2026 results showed a revenue beat ($4.51M vs. $4.34M estimate) but a wider loss ($0.13 per share vs. $0.10 estimate) due to rising costs. Bookings dropped 19% YoY to $1.9M, though 9-month bookings surged 611% to $37.4M. CEO Alan Baratz highlighted a strong pipeline. Rigetti (RGTI) fell 3%, while IonQ (IONQ) declined 0.34%.

$TLSIMed

TriSalus Life Sciences Reports Third Quarter 2026 Results

TriSalus Life Sciences, Inc. (TLSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. TriSalus Life Sciences Reports Third Quarter 2026 Results Generated third quarter revenue of $12.9 million, driven by expanded commercial organization and increasing market penetration Revised 2026 revenue guidance to $46 million to $48 million Centers for Medicare & Medicaid Ser